Financial Management Company Douglas Lane Raised Its Thermo Fisher Stake. Is the Stock a Buy?

Douglas Lane & Associates increased its stake in Thermo Fisher Scientific (NYSE:TMO) by 16,745 shares, a transaction valued at approximately $7.79 million, bringing its total holding to 216,276 shares, or 1.5% of its AUM as of September 30, 2025. This significant purchase suggests the wealth manager perceives TMO as attractively valued after its 12% stock decline over the past year, supported by the company's robust Q2 performance, which saw 3% revenue growth and a 6% EPS increase, alongside raised 2025 guidance to $44 billion.

Analysis

Douglas Lane & Associates significantly increased its position in Thermo Fisher Scientific (NYSE:TMO), purchasing 16,745 shares valued at approximately $7.79 million. This transaction, disclosed on October 10, 2025, brings their total holding to 216,276 shares, representing 1.5% of their AUM as of September 30, 2025, signaling a notable institutional endorsement. This move suggests Douglas Lane perceives TMO as attractively valued, especially after the stock experienced an approximate 12% decline over the trailing 12 months.

The investment thesis is further supported by TMO's robust operational performance and valuation metrics. The company reported a 3% revenue growth to $10.9 billion and a 6% year-over-year increase in diluted EPS to $4.28 for its fiscal second quarter, ending June 28. Furthermore, the article notes TMO's price-to-earnings (P/E) ratio is lower than a year ago, indicating a more favorable valuation.

Thermo Fisher also raised its 2025 fiscal guidance to approximately $44 billion in sales, an increase from the prior year's $42.9 billion. This upward revision, combined with consistent EPS growth and a diversified business model across life sciences, diagnostics, and biopharma services, underpins the company's strong fundamental trajectory and market leadership. The overall sentiment surrounding TMO is strongly positive, reflecting confidence in its future prospects.

Key Decisions for Investors

• Investors should consider TMO's current valuation, which appears attractive following a 12% stock decline and a lower P/E ratio compared to the previous year.
• Monitor TMO's continued operational performance, particularly its revenue and EPS growth, given the strong Q2 results and raised 2025 fiscal guidance.
• Evaluate TMO's long-term strategic positioning within the diversified life sciences and diagnostics sectors, as its market leadership and consistent growth trajectory present a compelling investment case.